Carolina Reduzzi

Assistant Professor

Weill Cornell Medicine

United States

Research Interests

Explore related searches

Professors in United States Professors in Tissue Engineering Tissue Engineering professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Carolina Reduzzi is an Assistant Professor at Weill Cornell Medicine in the United States. Her research primarily focuses on circulating tumor cells, liquid biopsy, and the dynamics of cancer therapies in metastatic breast cancer. Recent publications include studies on biomarkers in hormone receptor-positive metastatic breast cancer and the applications of machine learning in oncology.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Collaborators (3)

Eleonora Nicolò

Weill Cornell Medicine

UNITED STATES

View details

Kathy Miller

Indiana University Bloomington

UNITED STATES

View details

Massimo Cristofanilli

Northwestern University Feinberg School of Medicine

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Carolina Reduzzi

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Circulating Tumor Cell Dynamics after CDK4/6 Inhibitor for Hormone Receptor–Positive Metastatic Breast Cancer: A Biomarker Analysis from the PACE Phase II Study

Bone-Induced HER2 Promotes Secondary Metastasis in HR+/HER2− Breast Cancer

Integrating machine learning-predicted circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in metastatic breast cancer: A proof of principle study on endocrine resistance profiling

Mapping breast cancer therapy with circulating tumor cells: The expert perspective

Cancer in a Drop: Liquid biopsy insights from AACR 2025

Unveiling the impact of circulating tumor cells: Two decades of discovery and clinical advancements in solid tumors.

The role of liquid biopsy as a catalyst for sustained progress in precision oncology – Perspective of the young committee of the international society of liquid biopsy

Cellular residual disease (CRD) in early breast cancer –Expanding the concept of minimal residual disease monitoring?

Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer

Circulating Tumor DNA and Unique Actionable Genomic Alterations in the Longitudinal Monitoring of Metastatic Breast Cancer: A Case of FGFR2-KIAA1598 Gene Fusion

Collaborators (3)

Eleonora Nicolò

Kathy Miller

Massimo Cristofanilli

Make your next move.